Search Results
Jan 28, 2026, 14:23 ET $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock.Click
More news about: Monteverde & Associates PC
Jan 26, 2026, 12:34 ET 신젠 인터내셔널, 브리스톨 마이어스 스퀴브와의 장기 연구 협력 2035년까지 연장
강력한 데이터 보안, 세계적 수준의 제조 역량을 신속하게 제공하여 시장 출시 기간을 단축하고 혁신 비용을 절감한다.인도 및 미국 전역에 걸쳐 23만 제곱미터 이상의 전문적인 연구•개발•제조 시설을 보유한 신젠은 첨단 과학을 추구하는 바이오테크 기업과 BMS, GSK, Zoetis, Merck KGaA와 같은 다국적 기업을 포함한 다양한 산업 부문의 400여 글로벌 고객사와 협력하고 있다. 자세한 내용은 www.syngeneintl.com에서 확인할 수 있다.
More news about: Syngene International
Jan 21, 2026, 17:31 ET Cystinosis Market to Grow at a Substantial Growth Rate of 5.1% During the Forecast Period (2025-2034) | DelveInsight
Horizon Therapeutics PLC, Mylan N.V., Chiesi Farmaceutici SpA, Recordati Rare Disease, AVROBIO Inc., Leadiant Biosciences Inc., Eloxx Pharmaceuticals, GSK, among others.
More news about: DelveInsight Business Research, LLP
Jan 21, 2026, 11:18 ET A Syngene International estende a parceria de pesquisa de longo prazo com a Bristol Myers Squibb até 2035
com 400 clientes globais em diversos segmentos do setor, incluindo empresas de biotecnologia que buscam ciência de ponta e multinacionais como BMS, GSK, Zoetis e Merck KGaA. Para mais detalhes, acesse www.syngeneintl.com. Para
More news about: Syngene International
Jan 21, 2026, 11:17 ET Syngene International amplía la colaboración de investigación a largo plazo con Bristol Myers Squibb hasta 2035
clientes mundiales en todos los segmentos del sector, incluidas empresas de biotecnología que buscan ciencia de vanguardia y multinacionales como BMS, GSK, Zoetis y Merck KGaA. Para más información, visite www.syngeneintl.com. Para consultar el último
More news about: Syngene International
Jan 21, 2026, 11:14 ET Syngene International verlängert langfristige Forschungszusammenarbeit mit Bristol Myers Squibb bis 2035
verschiedenen Industriesegmenten zusammen, darunter Biotech-Unternehmen, die Spitzenforschung vorantreiben, und multinationale Unternehmen wie BMS, GSK, Zoetis sowie Merck KGaA. Weitere Informationen finden Sie auf www.syngeneintl.com.
More news about: Syngene International
Jan 21, 2026, 11:06 ET Syngene International 延長與 Bristol Myers Squibb 的長期科研合作至 2035 年
名科學家，兼具深厚專業實力與規模化交付能力，能夠迅速提供卓越的科學研發、穩健的數據安全保障以及世界級的製造服務，從而加快產品上市時程，並降低創新成本。Syngene 在印度及美國設有超過 250 萬平方呎的專業發現、開發及製造設施，服務約 400 家全球客戶，覆蓋多個行業領域，包括從事前沿科研的生物科技公司，以及 BMS、GSK、Zoetis 及 Merck KGaA 等跨國企業。 如欲了解更多詳情，請瀏覽 www.syngeneintl.com。 有關本公司最新的環境、社會及管治 (ESG)
More news about: Syngene International
Jan 21, 2026, 10:07 ET Syngene International、Bristol Myers Squibb社との長期共同研究を2035年まで延長
eneチームは、深い専門知識と、卓越した科学的知見、強固なデータセキュリティ、世界最高水準の製造技術を迅速に提供する能力を備え、市場投入までの時間を短縮し、イノベーションのコストを削減しています。インドと米国に250万平方フィートを超える専門的な探索、開発、製造施設を持つSyngeneは、最先端科学を追求するバイオテクノロジー企業や、BMS、GSK、Zoetis、Merck KGaAなどの多国籍企業を含む産業分野にわたって400社のグローバル顧客と提携しています。詳細はwww.syngeneintl.comをご覧ください。同社の最新の環境・社会・ガバナンス（ESG）レポートについては、「Syngene
More news about: Syngene International
Jan 21, 2026, 08:30 ET Syngene International prolonge jusqu'en 2035 sa collaboration à long terme avec Bristol Myers Squibb (BMS) dans le domaine de la recherche
mondiaux dans tous les segments du secteur, notamment des sociétés de biotechnologie à la pointe de la science et des multinationales telles que BMS, GSK, Zoetis ou Merck KGaA. Pour obtenir plus d'informations, veuillez consulter le site www.syngeneintl.com.
More news about: Syngene International
Jan 21, 2026, 05:04 ET Syngene International extiende su colaboración de investigación con Bristol Myers Squibb
con 400 clientes globales de diversos sectores, incluyendo empresas biotecnológicas que buscan la ciencia de vanguardia y multinacionales como BMS, GSK, Zoetis y Merck KGaA. Para más información, visite www.syngeneintl.com. Para
More news about: Syngene International
Jan 21, 2026, 00:40 ET Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights
click here to learn more about your legal rights and options.RAPT Therapeutics, Inc. (NASDAQ: RAPT)'s sale to GSK plc for $58.00 per share. If you are a RAPT shareholder,
More news about: Halper Sadeh LLP
Jan 20, 2026, 14:34 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock. Is
More news about: Monteverde & Associates PC
Jan 20, 2026, 12:51 ET Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
works with 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the
More news about: Syngene International
Jan 20, 2026, 12:41 ET Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
works with 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the
More news about: Syngene International
Jan 20, 2026, 12:15 ET Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
More news about: Ademi LLP
Jan 20, 2026, 08:00 ET Ouro Medicines Receives U.S. FDA Fast Track Designation for Gamgertamig in Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA and Norwest. For more information visit
More news about: Ouro Medicines
Jan 20, 2026, 02:55 ET Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
-- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ technology,
More news about: Alteogen Inc.
Jan 14, 2026, 23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab.WuXi Biologics' research services business achieved another record year in 2025, securing record-breaking
More news about: WuXi Biologics
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
Partners with new clinical programs in 2025 include Abogen, GSK, iTeos, Innovent, Invivyd, Kelonia Therapeutics, and Triveni Bio, among others.Adimab's latest partner program to receive approval is GSK's Exdensur
More news about: Adimab, LLC
Jan 13, 2026, 10:15 ET Inflammatory Diseases Biologics Market to Reach USD 157.31 Billion by 2033 as Targeted Immunology Therapies Redefine Long-Term Disease Control
precision medicine capabilities. The company maintains a strong presence in Europe and North America, with expanding reach in Asia-Pacific.GSKGSK is expanding its inflammatory disease biologics portfolio through targeted immunology research and next-generation antibody platforms. The company
More news about: DataM Intelligence 4 Market Research LLP
Jan 12, 2026, 14:57 ET Adimab Reports Strong Partnering Year for 2025
generating more than 650 therapeutic programs, 89 clinical programs, and 6 approved products. The Adimab technology has been transferred and implemented at GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Alnylam, Bristol Myers Squibb,
More news about: Adimab, LLC
Jan 12, 2026, 08:00 ET AlphaSense to Outline AI Trends Impacting Drug Discovery and R&D Investment in Biotech and Pharmaceutical Industries at Fierce JPM Week Conference
and R&D Investment in Biopharma," taking place at 11:20 a.m. PT on January 14. The panel, which also features leaders from AbbVie, Evidation, GSK, and Zoetis, will deliberate how AI is being applied to portfolio strategy and business development, AI's impact on research and development investment
More news about: AlphaSense
Jan 12, 2026, 07:00 ET Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
market confidence in the project. The global COPD market is estimated to reach USD 30.2 billion by 2033. Despite competition from MNCs like Merck and GSK in the PDE3/4 space, HSK39004 is poised to become the world's first dry powder inhaler targeting this mechanism, offering a paradigm-shifting treatment
More news about: Haisco
Jan 08, 2026, 13:05 ET Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer's
validated by funding support from top-tier organizations. This includes the new research grant from the Alzheimer's Association, a strategic alliance with GSK, prior funding from The Michael J. Fox Foundation, and funding from blue-chip biopharma investors, underscoring strong confidence in our resilience-based
More news about: Muna Therapeutics
Jan 08, 2026, 08:00 ET Flagship Pioneering Appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome
CFO, he guided Adaptimmune through its IPO and helped grow the company to more than 500 employees. Before Adaptimmune, he spent more than 15 years at GSK in senior global roles, including SVP of Finance for North American Pharmaceuticals, SVP of Worldwide Business Development and R&D Finance, where
More news about: Flagship Pioneering